Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability

Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory or autoimmune diseases. We assessed the effects of ruxolitinib on lipopolysaccharide (LPS)- and poly (I:C)-induced cytokin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantov, Nikola, Zrounba, Mathilde, Brollo, Marion, Grassin-Delyle, S, Glorion, Matthieu, David, Mélanie, Naline, Emmanuel, Devillier, Philippe, Salvator, Hélène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437255/
https://www.ncbi.nlm.nih.gov/pubmed/36059986
http://dx.doi.org/10.3389/fphar.2022.896167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437255/
https://www.ncbi.nlm.nih.gov/pubmed/36059986
http://dx.doi.org/10.3389/fphar.2022.896167

Ejemplares similares